Assessment of drug interaction potential between the hepatitis C virus direct-acting antiviral agents elbasvir/grazoprevir and the nucleotide analog reverse-transcriptase inhibitor tenofovir disoproxil fumarate | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Assessment of drug interaction potential between the hepatitis C virus direct-acting antiviral agents elbasvir/grazoprevir and the nucleotide analog reverse-transcriptase inhibitor tenofovir disoproxil fumarate

Feng HP, Guo Z, Caro L, et al. Assessment of drug interaction potential between the hepatitis C virus direct-acting antiviral agents elbasvir/grazoprevir and the nucleotide analog reverse-transcriptase inhibitor tenofovir disoproxil fumarate. Clin Pharmacol Drug Dev. 2019;8(7):962-970.

Publication Type:

Journal Article

Authors:

Feng, HP; Guo, Z; Caro, L; et, al

Source:

Clin Pharmacol Drug Dev, Volume 8, Issue 7, p.962-970 (2019)

Cited On:

Patients With HIV/HCV Coinfection

Export Citation:

RIS Format

Top